Medicines Manufacturing Innovation Centre Reports on myliquitab
The first study by the Medicines Manufacturing Innovation Centre reported: “The (myliquitab) system tested shows substantive advantages over traditional tablet crushing, as its operation … reduces tablet handling risks, reduces risk of drug loss, and removes arduous manual crushing operations”.
When used correctly, the myLiquitab System resulted in: “98% or greater of the drug dose delivered from the liquid dispersion”.
The report goes on to say that the ultrasonic energy used in the dispersion by myLiquitab is safe in use, and not considered harmful to the chemical stability of drug compounds in solid oral medications considered for use.
The myLiquitab flavouring agent had no observed effect on drug disintegration and was considered unlikely to have any unwanted effect on dosing. Medications can be mixed in the myLiquitab Homecare Unit without limiting dispersions formed and dispersion quality analysis indicated dispersions were consistent, very fine, and suitable for oral swallowing delivery in every case.
The second report conducted in collaboration with staff and students under the Monash University Pharmaceutical Science Course Industry Partnership Program found that the process of crushing tablets with a mortar and pestle or a tablet crusher appears ‘highly subjective’ and ‘an anticipated source of significant variation and potential error in delivery outcomes.’
In more than half the tablets tested in this study, the percentage of drug delivered from the manual tablet crushing process (as per guidance) was substantially inferior to the drug delivered from myliquitab. In three cases of tablet crushing, half or more of the dose was lost.
myLiquitab disperses rather than crushes medications.
For a copy of the study or for more information, please let the company know via the enquiry box on this page.